COYA THERAPEUTICS
Coya Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease. The company’s proprietary CTreg (cryopreservation for Tregs) system is the first in the industry to create an ‘off the shelf’ approach to Treg cell therapy allowing for serial infusions. Through our patented TAI (Tregs Against Inflammation) and EAITM (Exosomes Against Inflammation) platforms, Coya is focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Parkinson’s, Alzheimer’s, FTD and autoimmune diseases.
COYA THERAPEUTICS
Industry:
Biopharma Biotechnology Life Science
Founded:
2020-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.coyatherapeutics.com
Total Employee:
1+
Status:
Active
Contact:
1(800) 587-8570
Email Addresses:
[email protected]
Total Funding:
20.3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Font Awesome Apache Global Site Tag
Similar Organizations
ALX Oncology
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Atalanta Therapeutics
Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Vigil Neuroscience
Vigil Neuroscience is a biotechnology company that develops novel therapeutics for neurodegenerative diseases.
Current Employees Featured
Founder
Investors List
Allele Capital Partners
Allele Capital Partners investment in Series A - Coya Therapeutics
Key Employee Changes
Official Site Inspections
http://www.coyatherapeutics.com Semrush global rank: 2.71 M Semrush visits lastest month: 6.1 K
- Host name: 16.110.212.35.bc.googleusercontent.com
- IP address: 35.212.110.16
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Coya Therapeutics"
Clinical-Stage Biotech Developing Treg-based Therapies - Coya …
The organization provides resources to help ease the burden on patients and families facing these challenges. Daniel holds an MBA from Rice University and a B.S. in Mechanical Engineering …See details»
Coya Therapeutics - Investor Relations
Nov 6, 2024 [email protected]. Email Alerts. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting …See details»
Coya Therapeutics, Inc. | LinkedIn
Coya Therapeutics announces that, as previously disclosed, Arun Swaminathan, Ph.D., has been promoted to Chief Executive Officer, effective today, November 1.He brings a wealth of strategic ...See details»
Coya Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Phone Number 1(800) 587-8570 Coya Therapeutics is a clinical-stage biotechnology company developing multiple first-in-class and best-in-class approaches that enhance regulatory T cells …See details»
Coya Therapeutics, Inc. (COYA) Company Profile & Facts - Yahoo …
See the company profile for Coya Therapeutics, Inc. (COYA) including business summary, industry/sector information, number of employees, business summary, corporate governance, …See details»
Coya Therapeutics, Inc. (COYA) Company Profile & Overview
Dec 29, 2022 5850 San Felipe Street, Suite 500 Houston, Texas 77057 United StatesSee details»
Coya Therapeutics - Coya Therapeutics, Inc. and Dr. Reddy’s ...
Dec 6, 2023 Dr. Howard Berman, Chief Executive Officer of Coya observed: “The Coya team is delighted to enter this exciting partnership with Dr. Reddy’s, a world class organization that …See details»
Coya Therapeutics Secures $10 Million Financing to Advance …
Coya Therapeutics’ clinical and biomarker data continue to demonstrate regulatory T cells (Tregs) ability to meaningfully dampen both systemic and neuroinflammation, thereby restoring the …See details»
Coya Therapeutics - Coya Therapeutics Secures $10 Million …
Jun 7, 2022 Coya Therapeutics clinical and biomarker data continue to demonstrate regulatory T cells (Tregs) ability to meaningfully dampen both systemic and neuroinflammation, thereby …See details»
Coya Therapeutics - Craft
Aug 23, 2024 Coya Therapeutics has 2 employees at their 1 location and $6 m in annual revenue in FY 2023. See insights on Coya Therapeutics including office locations, …See details»
Coya Therapeutics to Present Novel Biomarker Survival Data in …
Feb 22, 2024 Novel biomarker data in ALS patients correlates to rate of progression and survival. HOUSTON, February 22, 2024--(BUSINESS WIRE)--Coya Therapeutics, Inc. …See details»
Coya Therapeutics - Overview, News & Similar companies
May 20, 2024 Coya Therapeutics contact info: Phone number: (800) 587-8170 Website: www.coyatherapeutics.com What does Coya Therapeutics do? Headquartered in Houston, …See details»
Coya Therapeutics™ Announces Formation of Scientific Advisory …
Feb 23, 2021 For more information, please visit www.coyatherapeutics.com Investor Contact Media Contact: Daniel Ferry 617-430-7576 [email protected]: Joleen Schultz 760 …See details»
Coya Therapeutics - Coya Therapeutics™ Completes Merger with …
Houston, TX., February 3, 2021 — Coya Therapeutics, Inc., (Coya™), a clinical-stage biotechnology company developing first-in-class approaches that utilize autologous regulatory …See details»
Coya Therapeutics - Coya Therapeutics Announces Successful Pre …
Jan 5, 2024 Coya has a clear path towards submission of the IND application to the FDA in the second quarter of 2024, with a planned initiation of a well-controlled, double-blind clinical trial …See details»
Coya Therapeutics, Inc. (COYA) Stock Price, Quote & News - Stock …
2 days ago Website https://www.coyatherapeutics.com. Full Company Profile. Financial Performance. Financial Statements. Analyst Forecast. According to 4 analysts, the average …See details»
Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of …
Phase 2a publication entitled “Combined Regulatory T-Lymphocyte and IL-2 Treatment is Safe, Tolerable, and Biologically Active for One Year in Persons with Amyotrophic Lateral Sclerosis” …See details»
Coya Therapeutics - Coya Therapeutics Announces $5 Million …
May 20, 2024 HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics …See details»
Coya Therapeutics - Coya Therapeutics Strengthens its …
Jun 14, 2023 Dr. Frazier brings over 20 years of strong regulatory expertise since her tenure at the FDA followed by a successful career in the pharmaceutical industry. Dr. Frazier spent 7 …See details»